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Acute coronary syndromes (ACS) are precipitated by a rupture of the atherosclerotic 
plaque, often at the site of T cell and macrophage infi  ltration. Here, we show that 
plaque-infi  ltrating CD4 T cells effectively kill vascular smooth muscle cells (VSMC). VSMCs 
sensitive to T cell–mediated killing express the death receptor DR5 (TNF-related apoptosis-
inducing ligand [TRAIL] receptor 2), and anti-TRAIL and anti-DR5 antibodies block 
T cell–mediated apoptosis. CD4 T cells that express TRAIL upon stimulation are expanded in 
patients with ACS and more effectively induce VSMC apoptosis. Adoptive transfer of 
plaque-derived CD4 T cells into immunodefi  cient mice that are engrafted with human 
atherosclerotic plaque results in apoptosis of VSMCs, which was prevented by coadminis-
tration of anti-TRAIL antibody. These data identify that the death pathway is triggered by 
TRAIL-producing CD4 T cells as a direct mechanism of VSMC apoptosis, a process which 
may lead to plaque destabilization.
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The rupture of the surface of atherosclerotic 
plaque, giving rise to superimposed thrombosis 
and arterial occlusion, is considered the most 
frequent primary cause for acute coronary syn-
dromes (ACS) such as unstable angina, myo-
cardial infarction, and sudden cardiac death (1, 
2). The atheroma’s vulnerability to rupture is 
correlated with a cellular infi  ltrate of macro-
phages and activated T cells in the plaque tissue 
(3–5). Macrophages have been implicated in 
destroying cells and matrix components and 
thus weaken the plaque structure (6–9). It is 
not known which signals trigger tissue-infi  l-
trating macrophages to secrete damaging en-
zymes. The infl  ammatory infi  ltrate also includes 
lymphocytes, mast cells, and dendritic cells, 
which may directly or indirectly contribute to 
plaque instability.
CD4 T cells, the dominant type of plaque-
residing T cells, undergo in situ activation in 
culprit lesions (4, 10, 11) and include expanded 
clonotypes with shared T cell receptor se-
quences, suggesting a role for antigen recogni-
tion in T cell activation (4). Plaque-infi  ltrating 
CD4 T cells are recruited from the CD4+CD28− 
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subset that is enriched in the blood of patients 
with ACS and typically produce high levels of 
IFN-γ (12, 13). These CD4 T cells have lost 
the costimulatory molecule CD28 (14) and, in-
stead, communicate with their microenviron-
ment through a new set of immunoreceptors 
(15), such as killer immunoglobulin-like recep-
tors. KIR2DS2 endows CD4 T cells with the 
ability to kill target cells, even in the absence of 
TCR triggering. CD4+CD28− T cells isolated 
from patients with ACS kill endothelial cells in 
vitro, making them a prime suspect for mediat-
ing endothelial injury (16). Apoptotic death of 
VSMCs has been proposed as a mechanism of 
plaque destruction, transforming a stable plaque 
into rupture-prone lesions (17, 18). Here, we 
have explored whether plaque-infi  ltrating CD4 
T cells directly cause VSMC apoptosis.
T cells kill target cells via two distinct ef-
fector pathways: fi  rst, by expelling cytotoxic 
granules containing perforin and granzyme; 
or, second, by ligating death receptors (19). 
CD8 T cells typically use granules to lyse tar-
get cells, whereas CD4 T cells preferentially 
mediate cell death through the production of 
TNF-like molecules, such as the membrane-
integrated protein Fas ligand (FasL) and APO2 240  TRAIL-MEDIATED KILLING OF VSMC | Sato et al. 
ligand/TNF-related apoptosis-inducing ligand (TRAIL) 
(20). TRAIL binds to type I transmembrane proteins such 
as TRAIL-R1 (DR4) and TRAIL-R2 (DR5) (21, 22) and 
triggers the formation of the death-inducing signaling 
complex that recruits procaspase-8 through the adaptor 
protein Fas-associated death domain (FADD) (23). Proteo-
lytically activated caspase-8 mediates the activation of ter-
minal eff  ector caspase-3 and causes target cell death. It is 
believed that TRAIL causes apoptosis of various tumors, 
but leaves normal cells unharmed and constitutes a physio-
logic pathway of CD4 T cell–mediated cytotoxicity against 
tumor cells (24, 25). However, TRAIL can also induce 
apoptosis of activated human T cells (26), neutrophils (27), and 
hepatocytes (28).
We show that VSMCs are susceptible to TRAIL-medi-
ated apoptosis, and that patients with ACS bear increased fre-
quencies of CD4 T cells that express TRAIL upon stimulation 
and kill VSMCs in a TRAIL-dependent manner. Adoptive 
transfer of such CD4 T cells causes VSMC death in human 
carotid plaque, demonstrating the in vivo relevance of this 
mechanism in plaque destabilization.
RESULTS
CD4 T cells induce VSMC apoptosis
To investigate whether plaque-infi  ltrating CD4 T cells can 
directly damage VSMCs, T cell lines and VSMC lines were 
established from infl  amed plaque tissue that was collected 
by carotid endarterectomy. CD4 T cell lines maintained by 
polyclonal stimulation were incubated on autologous and 
heterologous VSMC monolayers. As shown in Fig. 1, plaque-
derived CD4 T cells eff  ectively induced VSMC apoptosis. 
At an eff  ector–target ratio of 20:1, 60–70% of autologous 
VSMCs were killed within 4 h of coculture. Even at a low 
eff  ector–target ratio of 2.5:1, one third of the VSMCs un-
derwent apoptosis. VSMC apoptosis was absolutely depen-
dent on T cells; VSMC death in control cultures without T 
cells was minimal (Fig. 1, a and c). Apoptosis rates at low ef-
fector–target ratios increased with prolonged incubation for 
24–48 h (not depicted). Cytolytic activity was observed 
with heterologous VSMCs that were not matched for MHC 
polymorphisms with the responding T cell population; cy-
tolytic activity on autologous VSMCs derived from the T 
cell donor was only slightly higher (Fig. 1 a). All VSMC 
lines expressed MHC class I and HLA-DR molecules, as 
determined by confocal microscopy (unpublished data). 
Anti–HLA-DR antibodies blocked CD4 T cell–induced 
VSMC apoptosis in a dose-dependent manner; antibodies 
specifi  c for MHC class I molecules had no eff  ect (Fig. 1 b). 
These fi  ndings suggested that the VSMC killing involved 
interaction between MHC class II molecules and the T cell 
antigen receptor.
To examine whether the ability to induce VSMC apo-
ptosis was restricted to plaque-infi  ltrating T cells, CD4 T 
cells were isolated from the peripheral blood of patients with 
ACS and added to VSMC monolayers. CD4 T cells induced 
apoptosis in 40–50% of VSMCs (Fig. 1 c). Peripheral blood 
CD4 T cells were also able to kill both autologous and allo-
geneic VSMCs.
To assess whether CD4 T cells from patients with ACS 
had a higher ability to kill VSMCs, a cohort of 50 patients 
with either myocardial infarction (72% male, 60.9 ± 12.1 yr 
old) or unstable angina (72% male, 66.9 ± 12.4 yr old) was 
compared with 33 age-matched controls (58% male, 57.3 ± 
16.8 yr old). The VSMCs used for these experiments were 
derived from the coronary artery of a single donor (coronary 
artery smooth muscle cell [COR-SMC]). 20–25% of the 
VSMCs underwent apoptosis when exposed to PBMC-de-
rived CD4 T cells isolated from controls at an eff  ector–target 
ratioof 10:1. The rate of VSMC apoptosis was sub-stantially 
increased with T cells collected from peripheral blood of 
ACS patients (P = 0.0002) (Fig. 1 d). A similar increase in 
VSMC apoptotic activity was not   observed with CD4 T cells 
Figure 1.  CD4 T cells induce VSMC apoptosis. (a) CD4 T cell lines 
and VSMC lines were established from carotid endarterectomy samples of 
4 patients. CD4 T cells were expanded and incubated on heterologous 
(open bar) or autologous (shaded bar) SMC monolayers at indicated 
  effector–target cell ratios. VSMC apoptosis was assessed by DAPI staining 
after 4 h of coculture. Results from a representative experiment are shown 
as mean ± SD of triplicates. VSMC apoptosis in cultures without added 
T cells (indicated as control) was minimal. (b) Coronary SMCs were pre-
treated with increasing concentrations of anti-HLA class I mAb (W6/32) or 
anti–HLA-DR mAb (L243) for 1 h, and then cocultured with CD4 T cells at 
an effector–target ratio of 10:1 for 4 h before apoptosis analysis. Results 
from one of seven experiments are shown as mean ± SD of triplicate 
cultures. (c) CD4 T cells were isolated from PBMC by negative selection 
and added to heterologous VSMC monolayers at indicated effector–target 
cell ratios. Frequencies of apoptotic VSMCs were determined after 4 h. 
Results are shown as mean ± SD of triplicates and are representative of 
eight patients with acute coronary syndrome (ACS). Controls indicate 
VSMCs without added T cells. (d) PBMC-derived CD4 T cells from 50 
  patients with ACS and from 33 normal controls (NC) were incubated on 
coronary-SMC monolayers for 4 h at an effector–target ratio of 10:1. 
Frequencies of apoptotic cells are shown as box plots displaying medians: 
25th and 75th percentiles as boxes; and 10th and 90th percentiles as 
whiskers. Patient-derived CD4 T cells induced VSMC death at signifi  cantly 
higher frequencies (P = 0.0002 by Mann-Whitney U test) than those 
from controls.JEM VOL. 203, January 23, 2006  241
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from   patients with stable coronary artery disease (unpublished 
data). These data demonstrated that VSMCs were susceptible 
to T cell–mediated death, and that CD4 T cells from patients 
with ACS had higher VSMC cytotoxicity.
CD4 T cell–mediated VSMC apoptosis depends 
on the death pathway
T cells can kill target cells by diff  erent pathways; e.g., by re-
leasing lytic enzymes or by triggering of the death pathway 
(19, 29, 30). Clustering of cell surface death receptors initi-
ates death pathway–induced apoptosis via FADD recruitment 
and eventual caspase-8 activation. As shown in Fig. 2 a, cas-
pase-8/granzyme B blocking in VSMCs resulted in a marked 
inhibition of VSMC apoptosis (P = 0.006 in ACS patients). 
Inhibition of apoptosis induced by CD4 T cells from normal 
donors was more variable. To lend further support to the as-
sertion that VSMCs were killed via death pathway triggering, 
CD4 T cells were incubated on VSMCs transfected with 
dominant-negative (DN)–FADD–GFP or control GFP plas-
mid (Fig. 2 b). Blocking the function of FADD led to a 
marked decrease in the apoptosis rate (P = 0.02). These ex-
periments established that CD4 T cells induced VSMC apo-
ptosis by triggering the death pathway.
VSMCs express death receptors and are susceptible 
to TRAIL-mediated apoptosis
The expression of death receptors on VSMCs was examined 
by RT-PCR and FACS analysis. RT-PCR yielded positive 
results for three death receptors, DR4, DR5, and Fas. The 
transcripts for DR5 and Fas were abundant, whereas the signal 
for DR4 was only faint (Fig. 3 a). To assess surface expression 
Figure 2.  Death pathway dependence of CD4 T cell–mediated 
VSMC apoptosis. (a) CD4 T cells from four patients with ACS (left) and 
four control subjects (NC, right) were added to coronary SMC monolayers 
that had been pretreated with medium (control) or caspase-8/granzyme B 
Inhibitor I (25 μg/ml) for 1 h. The frequencies of apoptotic VSMCs are 
shown as mean ± SD of triplicate cultures. (b) VSMCs propagated in 
  collagen-coated 96-well plates were transfected with either GFP (control) 
or DN-FADD-GFP (0.05 μg/well). CD4 T cells from patients with ACS (n = 4, 
left panel) and NC (n = 4, right panel) were added at an effector–target 
cell ratio of 10:1. Frequencies of apoptotic VSMCs are shown as mean ± 
SD of triplicates. Results of control and treated samples were compared 
by Wilcoxon sign rank test.
Figure 3.  VSMCs express death receptors and are susceptible to 
TRAIL-mediated apoptosis. (a) Expressions of DR4, DR5, and Fas mRNA 
in VSMC were tested by RT-PCR. Results representative of experiments with 
10 coronary (COR-SMC) and carotid artery-derived cell lines (CA-SMC) are 
shown. There was consistent expression of Fas and DR5 in all lines; in par-
ticular, there was no difference between COR-SMC and CA-SMC. (b) Sur-
face death receptor expression on COR-SMCs and CA-SMCs was evaluated 
by FACS analysis. Histograms are representative of fi  ve experiments. Results 
from staining with antibodies specifi  c for DR4, DR5, and Fas are shown as 
open histograms; background fl  uorescence with isotype-matched control 
antibody is indicated by shaded histograms. (c) Sensitivity of VSMC to 
TRAIL-mediated apoptosis was assessed by culturing VSMC without (con-
trol) or with 400 ng/ml of recombinant human (rh)-soluble Flag-tagged 
TRAIL (rh-TRAIL) along with cross-linking 2 μg/ml of anti-FLAG antibody 
M2 for 12 h. Apoptotic cells were identifi  ed by DAPI staining. Results from 
one of four experiments are shown as mean ± SD of triplicate cultures.242  TRAIL-MEDIATED KILLING OF VSMC | Sato et al. 
of these receptors, VSMCs were stained with antibody and 
analyzed by FACS. DR5 and Fas were present at high mem-
brane density, whereas DR4 was not detected (Fig. 3 b).
To examine whether VSMCs are sensitive to death recep-
tor–mediated killing, VSMCs were incubated with rh-TRAIL. 
Apoptotic cells were identifi  ed according to morphology and 
DAPI nuclear staining. Cells that were spread out on the sur-
face and displaying normal nuclei were considered viable, 
whereas cells that had acquired a round shape and fragmented 
nuclei were considered apoptotic. Rh-TRAIL was highly ef-
fective in inducing apoptosis. After 12 h of exposure, >50% 
of cells had typical nuclear disintegration and lost adherence to 
the surface (Fig. 3c).
To examine whether DR5 expression in VSMC lines appro-
priately refl  ected tissue resident cell phenotypes in the athero-
sclerotic plaque, serial frozen sections from carotid arteries were 
stained with anti-CD68 mAb, to identify tissue-infi  ltrating 
macrophages; with anti–α-smooth muscle cell actin, to identify 
VSMCs; and with anti-DR5 antibody (Fig. 4). Atherosclerotic 
plaques were identifi  ed by oil-red staining. The plaque-free ca-
rotid artery wall served as the control. DR5 was expressed on 
VSMCs in the plaque cap region, but not on VSMCs in normal 
carotid artery walls.
CD4 T cells induce VSMC apoptosis through TRAIL
To determine whether TRAIL or FasL were involved in CD4 
T cell–mediated VSMC injury, anti-TRAIL and anti-FasL 
antibodies were added to the T cell–VSMC cultures. As 
shown in Fig. 5 a, TRAIL-reactive antibody inhibited VSMC 
apoptosis. In the presence of control antibody,  45% of 
VSMCs were killed at an eff  ector–target ratio of 5:1. To reach 
similar levels of apoptosis in the presence of anti-TRAIL mAb, 
four times as many T cells (eff  ector–target ratio of 20:1) were 
necessary, suggesting that TRAIL was responsible for >75% 
of the cytotoxic activity. Antibodies blocking Fas–FasL in-
teraction had no eff  ect on the level of VSMC apoptosis. In-
hibition by anti-TRAIL antibody was only seen for the CD4 
T cells deriving from ACS patients. Apoptosis levels in control 
T cell cultures were unaff  ected by TRAIL blockade. Similar 
results were obtained in experiments using anti-DR5 antibod-
ies. The rate of VSMC apoptosis induced by CD4 T cells 
from ACS patients was reduced by  50% when the TRAIL–
DR5 interaction was inhibited by anti-DR5 Ab (Fig. 5 b).
To examine whether TRAIL-expressing CD4 T cells 
were increased in frequency in patients with ACS, PBMC 
from patients and age-matched controls were analyzed by 
FACS for the membrane expression of TRAIL. TRAIL ex-
pression on CD4 T cells required cell activation; spontaneous 
expression was absent in ACS patients and controls. This re-
sult was consistent with the observation that cytotoxic activ-
ity was dependent on the recognition of HLA-DR molecules 
(Fig. 1 b). After TCR triggering, TRAIL expression was sig-
nifi  cantly increased (P = 0.002) in ACS patients compared 
with controls (Fig. 5 c).
Figure 4.  VSMCs in atherosclerotic plaque express TRAIL-R2/DR5. 
Serial frozen sections from normal carotid artery wall (a) and carotid 
  artery plaque (b) were stained with hematoxylin-eosin, oil-red, anti-CD68 
mAb, anti–α-smooth muscle cell actin Ab,and anti-DR5 Ab. Bound pri-
mary antibodies were visualized with DAB (brown).Original magnifi  cations 
of × 40 (top) and × 200   (bottom) are shown. Bars; (top) 500; (bottom) 
100 μm. Insets represent higher magnifi  cation of areas indicated 
by arrows. Results are   repre  sentative for immunohistochemistries 
from 11 carotid artery plaques.JEM VOL. 203, January 23, 2006  243
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CD4 T cells induce VSMC apoptosis 
in atherosclerotic plaque
To test the relevance of CD4 T cell–mediated killing of 
VSMCs in vivo, we implanted carotid plaque tissue into im-
munodefi  cient mice and adoptively transferred CD4 T cells 
into the chimeras. Mice engrafted with carotid artery speci-
mens lacking atherosclerotic plaques served as controls. T cell 
lines were established from a plaque of the same artery that was 
implanted into the mice. 7 d after implantation, full engraft-
ment was achieved, and 6 × 106 CD4 T cells were injected in-
travenously into the chimeras; 24 h later, the human tissue 
grafts were explanted. In addition to the adoptive transfer ex-
periments in which the T cells and atheroma tissue derived 
from the same donor, CD4 T cell lines were also injected into 
chimeras engrafted with heterologous tissue. Infi  ltration  of 
adoptively transferred T cells into the graft tissue was assessed 
by quantifying TCR-specifi  c transcripts. TRAIL expression in 
the tissue, before and after T cell transfer, was measured by 
real-time PCR. As shown in Fig. 6 a, T cell–derived TCR 
mRNA was low in control carotid wall grafts that lacked 
plaque formation. In contrast, TCR sequences in the tissue in-
creased more than fourfold, from a median of 1,800 copies to 
a median of 7,508 copies when CD4 T cells were injected into 
chimeras implanted with actively infl   amed carotid artery 
plaque. In parallel, the tissue expression of TRAIL in the 
plaque tissue increased 2.5-fold, whereas levels remained un-
changed in control tissue. Results were similar, irrespective of 
whether adoptively transferred CD4 T cells and plaque tissues 
derived from the same or diff  erent patients. These data sug-
gested that the infl  amed plaque tissue facilitated CD4 T cell re-
cruitment and retention and that the infi  ltration of CD4 T cells 
into the tissue site was associated with enhanced expression 
of TRAIL.
To determine whether adoptive transfer of CD4 T cells 
induced VSMC apoptosis, tissue sections of the explanted 
grafts were analyzed for the frequency of TUNEL+ cells. As 
expected, the frequency of TUNEL+ cells was higher in the 
plaques than in noninfl  amed control wall sections (Fig. 6 b). 
Areas with apoptotic cells were patchy and cosegregated with 
areas containing infl  ammatory infi  ltrates. After CD4 T cell 
transfer, distribution patterns of apoptotic cells continued to 
be discontinuous. Immunohistochemical stains showed 
that VSMCs accounted for the majority of apoptotic cells 
in the lesion (Fig. 6 b). The percentage of TUNEL+ 
cells in these patchy areas with infl  ammatory infi  ltrates in-
creased from 20% to >60% in the adoptively transferred 
mice (Fig. 6 c), demonstrating that infusion of CD4 T cells 
resulted in massive VSMC injury.
CD4 T cells mediate VSMC apoptosis in vivo through 
the TRAIL pathway
To examine whether the TRAIL pathway was involved in 
CD4 T cell–mediated apoptosis in vivo, TRAIL-blocking an-
tibodies were included in the adoptive transfer experiments. 
6 × 106 CD4 T cells were coadministered with anti-TRAIL 
mAb into chimeras implanted with autologous carotid tissue. 
As controls, mice implanted with the same tissue were either 
treated with 6 × 106 CD4 T cells combined with isotype-
matched control antibody or injected with control antibody 
only. Results shown in Fig. 7 demonstrated that 10–20% of the 
cells in the infl  amed plaque tissues recovered from mice treated 
with only control IgG antibody were apoptotic. Adoptive 
transfer of CD4 T cells in combination with control IgG anti-
body resulted in massive apoptosis in the lesion. After injecting 
Figure 5.  CD4 T cell–induced VSMC apoptosis is TRAIL-mediated. 
(a) CD4 T cells from patients with ACS and normal controls (NC) were 
pretreated with anti-Fas ligand, anti-TRAIL, or isotype control IgG2a anti-
body. After 1 h, T cells were added to VSMC monolayers at the indicated 
effector–target ratios. Frequencies of apoptotic VSMCs were assessed 
after 4 h. Apoptosis rates are given as mean ± SD of triplicate cocultures. 
Results are representative of fi  ve ACS patients. (b) CD4 T cells from an 
ACS patient were cocultured with VSMCs in the presence of a soluble-
anti-DR5 mAb or isotype-matched control IgG at an effector to target 
ratio of 20:1. Apoptotic rates were determined after 4 h and are given as 
mean ± SD of triplicate cultures. (c) Peripheral blood lymphocytes were 
stimulated with cross-linked anti-CD3 for 2 h, and TRAIL expression on 
CD4 T cells was examined by fl  ow cytometry. Results from 20 patients 
with ACS and 20 age-matched controls are shown as box plots.244  TRAIL-MEDIATED KILLING OF VSMC | Sato et al. 
Figure 6.  Adoptively transferred CD4 T cells infi  ltrate into athero-
sclerotic plaque and induce apoptosis. (a) Carotid artery plaque tissue 
(CAP) and control carotid artery wall lacking plaque were implanted into 
SCID mice. 7 d after implantation, the chimeras received 6 × 106 CD4 T 
cells (shaded bars) or PBS (open bars) by intravenous injection. 24 h later, 
the human tissue grafts were explanted, and TCR α-chain mRNA and 
TRAIL mRNA were measured by real-time PCR. cDNA concentrations were 
adjusted to 200,000 copies β-actin. Results from one of eight experi-
ments are shown as mean ± SD of triplicate measurements. (b) Control 
carotid artery tissue and carotid artery plaque tissue were engrafted into 
mice. 6 × 106 CD4 T cells were adoptively transferred into the mice; con-
trol animals received PBS. Apoptotic cells were detected by staining for 
TUNEL+ cells (Vector red). Representative immunofl  uorescence images 
(top, original magnifi  cation, 100) and immunohistochemistry images 
(middle, original magnifi  cation, 200) are shown. Bars: (top) 200 μm; 
 (middle)  100  μm. Staining of serial sections showed that TUNEL+ cells are 
α-smooth muscle actin-expressing cells and not CD3+ cells (bottom, 
original magnifi  cation, 100; insets, 400). Bars, 500 μm. (c) Quantitative 
assessment of apoptotic cells in arterial control and plaque tissue (CAP) 
that had been engrafted into immunodefi  cient mice is shown. Mice were 
given PBS (open bars) or were adoptively transferred with CD4 T cells 
(shaded bars). Data are expressed as the mean ± SD percentage of 
TUNEL+ cells in fi  ve visual fi  elds and are representative of eight adoptive 
transfer experiments.JEM VOL. 203, January 23, 2006  245
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CD4 T cells, >70% of VSMCs in the lesion stained TUNEL+ 
(Fig. 7 a). Apoptosis rates returned to baseline when CD4 T 
cells were coadministered with TRAIL-blocking antibody. In 
contrast, TCR mRNA in the tissues was equal, irrespective of 
whether anti-TRAIL or control Ab was administered, indicat-
ing that anti-TRAIL Ab did not infl  uence T cell infi  ltration 
and survival.
To use a diff  erent measure of VSMC death, we analyzed 
the leakage of lactate dehydrogenase (LDH) from the arterial 
tissue. As shown in Fig. 7 b, the activity of LDH in the chi-
meras’ blood remained stable for >24 h in mice treated with 
control antibody. Infusion of 6 × 106 CD4 T cells resulted in 
a twofold increase in LDH activity, supporting the interpre-
tation that the T cells had a direct role in damaging VSMCs. 
This T cell–mediated enhancement of LDH activity could be 
blocked by coadministration of anti-TRAIL antibody. These 
data demonstrated that CD4 T cells have a role in inducing 
VSMC apoptosis in vivo and that they use TRAIL to trigger 
VSMC death.
DISCUSSION
The loss of VSMCs in the fi  brous cap and accelerated degrada-
tion of the collagen matrix have been postulated as critical 
mechanisms in transforming stable plaque into rupture-prone 
lesions (31, 32). We have demonstrated that CD4 T cells kill 
cultured VSMCs by expressing the TNF-like ligand TRAIL 
and by triggering death receptors on the surface of VSMCs. 
Patients with ACS have higher frequencies of apoptosis-inducing 
CD4 T cells in circulation, suggesting an abnormality in T cell 
diff  erentiation that predisposes these patients to T cell–mediated 
VSMC damage, plaque rupture, and ischemic manifestations 
of atherosclerosis.
Recent evidence suggests that the thin-cap fi  broatheroma 
is the major precursor lesion to ACS (31). Plaque-infi  ltrating 
macrophages have been implicated in plaque destabilization 
through the production of metalloproteinases and, possibly, 
other tissue-injurious mediators (7–9, 33). Macrophages cul-
tured with VSMCs for 7 d kill VSMCs in a Fas–Fas ligand and 
TNF-dependent manner (8, 9). Also, unstable lesions contain 
a high frequency of activated T cells, which could directly 
promote the death of plaque-residing cells (10, 11, 34). Apop-
totic cells can be identifi  ed in the unstable plaque in vivo and 
include cells of the infl  ammatory infi  ltrate but also VSMCs 
(18, 35, 36); the absolute number of apoptotic VSMCs in these 
studies is likely an underestimate given that apoptotic cells are 
rapidly cleared by macrophages in vivo. In the present study, 
CD4 T cells equipped to induce apoptosis of cultured VSMCs 
not only accumulated in the plaque, but also circulated in the 
blood of patients with ACS. In vivo studies with human ca-
rotid plaque–SCID chimeras confi  rmed the ability of CD4 T 
cells to infi  ltrate into the lesion and mediate VSMC killing. 
The human–mouse chimera model likely is a more sensitive 
system to assess apoptosis than the natural host because the 
chimeric mice do not have   circulating human monocytes, and 
Figure 7.  TRAIL-expressing CD4 T cells mediate VSMC apoptosis 
in vivo. CD4 T cells were isolated from carotid artery plaque and expanded 
in vitro. SCID mice were implanted with pieces of the same plaque tissue. 
Engrafted mice received an intravenous administration of control IgG2a 
(300 μg/mouse; open bars), 6 × 106 CD4 T cells and control IgG2a (300 μg/
mouse; shaded bar), or 6 × 106 CD4 T cells and anti-TRAIL antibody 
(300 μg/mouse; shaded bar). Blood was drawn from the mice before and 
24 h after T cell transfer. Human artery grafts were harvested 24 h after 
treatment and processed for immunohistochemistry. (a) Apoptosis rates in 
tissue-residing cells were measured by the TUNEL assay. Results from one 
of eight experiments are shown as mean ± SD of triplicate visual fi  elds. 
(b) CD4 T cell–mediated injury of VSMCs in the tissue was estimated by 
determining the activity of LDH in the serum of the chimeras. Results are 
expressed as the mean ± SD fold-increase of LDH activity after T cell trans-
fer and are representative of eight experiments. (c) Immunohistochemistry 
stains from a representative adoptive experiment are shown. Compared 
with the spontaneous rate of TUNEL+ cells (green fl  uorescence, left), injec-
tion of autologous CD4 T cells caused a marked increase of apoptotic cells 
(middle). Anti-TRAIL mAb coadministration prevented the increased apopto-
sis after CD4 T cell transfer (right). Original magnifi  cation, 100. Bar, 200 μm.246  TRAIL-MEDIATED KILLING OF VSMC | Sato et al. 
murine monocytes hardly enter the human tissue. The inhibi-
tory eff  ect of anti-TRAIL, both in vitro and in vivo, estab-
lished that this TNF-like molecule was the major inducer of 
VSMC apoptosis.
T cells have been implicated in the pathogenesis of ath-
erosclerosis and probably contribute to multiple aspects of the 
disease process (37). They consistently accumulate in com-
plex lesions; and T cell defi  ciency reduces lesion size and cel-
lular infi  ltration (38, 39). Also, multiple cytokines intimately 
involved in T cell function (such as IL-15, IL-12 and IL-18), 
are expressed in the lesions and directly regulate plaque in-
fl  ammation and lesion size (40–43). We focused on T cells 
as eff  ector cells and not on their role as key regulators of 
in situ immunity. CD4 T cells, the dominant lymphocyte 
population in human atheromas, are usually not considered 
to lyse neighboring cells. However, CD4 T cells isolated 
from lesions that cause fatal myocardial infarction have a 
unique phenotype and functional profi  le (4, 13). They lack 
expression of CD28 and, instead, have acquired a new set of 
immunoregulatory receptors. Stimulation of killer immuno-
globulin-like receptors, selectively expressed on CD4 T cells 
in ACS, facilitates cytolysis and has been shown to lyse endo-
thelial cells (15, 16).
TCR triggering induces TRAIL expression on T cells, 
but cytokines, such as IFNs, can modulate this response (44). 
TRAIL is stored in cytoplasmic vesicles and can be rapidly 
brought to the cell surface. Spontaneous expression of surface 
TRAIL on CD4 T cells from patients with ACS is not in-
creased, suggesting that cross-linking of the TCR is necessary 
to initiate the cascade leading to T cell–mediated cytotoxicity. 
This is further supported by the fi  nding that the activity of 
CD4 T cells is dependent on the recognition of MHC class II 
molecules. Diff  erent antigens have been implicated in driving 
the response of T cells in the atherosclerotic lesion, including 
oxidized low density lipoprotein (45, 46) and chlamydial heat 
shock proteins (47). CD4+CD28− T cells proliferate when 
activated with HSP60 (48). The possibility remains that a 
spectrum of antigens, not just a single antigen, is responsible 
for the stimulation of tissue-infi  ltrating T cells. T cells from 
patients with ACS are prematurely aged and have characteris-
tics of senescent cells (49). Senescent T cells are less stringent 
in antigen-specifi  c responses to enter activation. Cumulative 
gene expression of regulatory molecules can partially or some-
times even completely substitute for TCR-mediated signals, 
rendering T cells responsive to antigen-nonspecifi  c cues in 
their microenvironment (15, 50). This may also explain why 
CD4 T cell–induced apoptosis, although dependent on the 
recognition of MHC class II molecules, was not restricted by 
MHC polymorphisms.
TRAIL is best known for its tumoricidal activity. Re-
combinant soluble forms of TRAIL have been found to in-
duce cell death predominantly in transformed cells while not 
aff   ecting normal tissues. However, TRAIL receptors are 
widely expressed on many cell types, and the physiologic 
functions of this TNF family member appear to be rather 
broad (21, 51). Besides playing a suspected role in T cell and 
NK cell tumor immunosurveillance, TRAIL has been impli-
cated in the thymic clonal deletion of autoreactive T cells and 
may be involved in peripheral homeostatic T cell compart-
ment control (26, 52). Data presented here reinforce previous 
papers asserting that TRAIL causes tissue injury in untrans-
formed cells. In cholestatic hepatocyte injury, bile acids faci-
litate TRAIL receptor oligomerization and activation (53). 
Human endothelial cells were found to express DR4 and 
DR5, and  30% were susceptible to TRAIL-induced apop-
tosis. When TRAIL was injected into human skin xenografts, 
it caused focal injury to tissue-residing endothelial cells (54). 
Other cell types susceptible to TRAIL-mediated apoptosis 
include developing erythrocytes (55), prostate cells, and T 
lymphocytes. Controversial results have been reported re-
garding TRAIL’s eff  ect on normal T lymphocytes, ranging 
from apoptosis resistance (56) and induced cell cycle arrest 
without cell death (57) to TRAIL-stimulated apoptosis 
(58). Also, studies on TRAIL’s critical role in establishing and 
maintaining immunologic tolerance by regulating negative 
selection of thymocytes have not been confi  rmed by other 
investigators (59). Insensitivity to TRAIL’s apoptotic eff  ects 
has been recently associated with the high expression of 
FLICE inhibitory protein, which provides a mechanism 
through which TRAIL-producing T cells and NK cells pro-
tect themselves while using TRAIL to kill DR5-expressing 
target cells (56).
VSMCs, both in the atherosclerotic plaque as well as in vi-
tro, strongly expressed DR5, whereas DR4 was essentially ab-
sent. Within hours, recombinant TRAIL induced apoptosis in 
the majority of cultured VSMCs. Such cultured DR5-express-
ing VSMCs were highly sensitive to TRAIL-expressing CD4 
T cells. In vivo transfer of CD4 T cells resulted in an increase 
of apoptotic VSMCs in the plaque, which could be blocked by 
anti-TRAIL Ab. CD4 T cells able to be activated by VSMC 
and to express TRAIL on the cell surface are abundant in ACS 
patients. A previous study has shown that these T cell abnor-
malities are not short-lived, likely precede the acute event, and 
certainly persist over time (12). Also, the presence of such T 
cells is not unique for ACS but is also found in other chronic 
diseases (60). The sole presence of such T cells is therefore not 
suffi   cient to precipitate disease manifestations. Rather, rate-
limiting steps may be the access of these T cells to the vascular 
wall compartment and expression of DR5 on VSMCs. The 
mechanisms of DR5 expression are unknown, but the suscep-
tibility of VSMCs to TRAIL-mediated apoptosis was such that 
it should raise concerns when considering using TRAIL as an 
anti-tumor agent in humans. T cells may gain access to the 
atherosclerotic plaque in patients with ACS via one of two 
routes: they may enter from the macrolumen; or, more likely, 
they may enter from the network of microcapillaries that de-
velops in the unstable plaque. The mouse chimera model only 
partially resembles this situation, because T cells must enter 
exclusively from the microvasculature. Regardless, recruit-
ment will be driven by chemokines produced in the tissue, and 
these chemokines are likely responsible for the preferential re-
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  artery tissue as shown in Fig. 6. Once in the tissue, CD4 T 
cells are being activated and exert eff  ector functions through 
TRAIL (Fig. 7).
Implicating CD4 T cells and their ability to up-regulate 
TRAIL surface expression in plaque destabilization could 
have direct consequences for the therapeutic approach to pa-
tients with vulnerable lesions. Inhibiting TRAIL or TRAIL-
producing CD4 T cells and restoring resistance to DR5 
triggering in VSMCs could have therapeutic potential for the 
acute management of patients with unstable angina and myo-
cardial infarction.
MATERIALS AND METHODS
Study population. 25 consecutive patients admitted with ST elevation 
myocardial infarction and 25 patients treated for unstable angina were enrolled 
in this study. Blood samples were drawn at the time of admission and pro-
cessed immediately. 33 age- and sex-matched control subjects had no history 
of autoimmune disease and no risk factors for cardiovascular disease. Control 
patients with stable coronary artery disease were matched for common risk 
factors such as hyperlipidemia, smoking, diabetes mellitus, and hypertension. 
Carotid artery specimens were collected from patients undergoing endarterec-
tomy procedures. All specimens were examined for the presence and absence 
of infl  ammatory infi  ltrates and plaque. End fragments of the specimens lacking 
plaque formation and mononuclear cell infi  ltrate were used as controls. The 
protocols were approved by the Mayo Clinic Institutional Review Board and 
the Emory University Institutional Review Board, and appropriate consent 
was obtained.
Cells. CD4 T cells were isolated from PBMC by negative selection (Roset-
teSep; StemCell Technologies, Inc.). Purity was 95–98%. Importantly, puri-
fi  ed cells did not include any NK cells. Human COR-SMCs were grown on 
collagen-coated tissue culture plates in SmGM-2 smooth muscle medium 
(Cambrex). Human carotid artery smooth muscle cell lines (CA-SMC) were 
established from carotid artery plaque using previously described methods 
(61). T cell lines were isolated from carotid endarterectomy samples by cul-
turing tissue fragments with 50 U/ml recombinant human (rh) IL-2 (CHI-
RON). After 7 d, tissue-derived T cells were stimulated with 106/ml 
irradiated PBMCs, 1.5 × 105/ml irradiated EBV-transformed B cells, 30 ng/ml 
anti-CD3 mAb (Ortho-Clinical Diagnostics), and 50 U/ml rh-IL-2. CD4 T 
cells were purifi  ed by fl  uorescence-activated cell sorting. Phenotypically, tis-
sue-derived CD4 T cells were diff  erent from peripheral CD4 T cells in that 
they all expressed memory markers and the frequency of CD28 loss was in-
creased (unpublished data).
Analysis of VSMC apoptosis. Apoptosis assays were performed using 
  nuclear fragmentation and condensation of VSMC stained with 4’, 6-di-
amidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich) as read-
out. Pilot studies showed an excellent correlation of the apoptosis rates by 
DAPI staining and by Annexin V staining (Fig. S1, available at http:// 
www. jem. org/ cgi/ content/ full/ jem. 20051062/ DC1).  Also, costaining of 
Annexin-positive VSMCs with PI clearly indicated that cell damage was ir-
reversible. To control for subjective interpretation, the reader was blinded as 
to whether the T cells derived from a patient or control individual. COR-
SMCs and CA-SMCs that reached confl  uence were seeded into collagen-
coated 96-well plates at a cell density of 104 SMCs/well and incubated with 
1 μg/ml DAPI in RPMI supplemented with 1% FBS for 1 h at 37°C. Cul-
tures were washed and purifi  ed. CD4 T cells or resting CD4 T cell lines 
were added to the VSMC monolayer for 4 h at 37°C. VSMCs were exam-
ined with fl  uorescence microscopy, and apoptosis rates were determined. 
Parallel assays were performed by staining for 4 h T cell–VSMC cocultures 
with Annexin V. In selected experiments, COR-SMCs were preincubated 
for 1 h with 1.25 μg/ml to 10 μg/ml anti-MHC class-ABC mAb (W6/32) 
or anti–HLA-DR mAb (L243) before coculture with T cells. In other 
  experiments, COR-SMCs were transfected with a DN-FADD-GFP–con-
taining plasmid (0.05 μg/well; pcDNA3-GFP-∆FADD, a gift from G.J. 
Gores, Mayo Clinic, Rochester, MN) or a GFP-expressing control plasmid 
pE-GFP-N1 using Opti-MEM I (100 μl/well; Invitrogen-GIBCO) contain-
ing LipofectAMINE (0.4 μg/well; Invitrogen-GIBCO) and LipofectAMINE 
Plus reagent (0.6 μl/well; Invitrogen) (53). Cells were incubated for 4 h at 
37°C in a 5% CO2, 95% air incubator. 24 h later, transfection effi   ciency was 
determined by analyzing GFP expression using fl  uorescence  microscopy. 
In other experiments, COR-SMCs were treated with a caspase-8/granzyme 
B inhibitor (25 μg/ml; caspase-8 inhibitor I; Calbiochem) for 1 h before 
apoptosis analysis.
To investigate the sensitivity of VSMCs to TRAIL-mediated apoptosis, 
VSMCs were incubated with 400 ng/ml of rh-soluble Flag-tagged TRAIL 
(Qbiogene) and 2 μg/ml of cross-linking FLAG-tagged antibody M2 (Sigma-
Aldrich) for 12 h before being analyzed for typical nuclear fragmentation.
To inhibit Fas–Fas ligand–mediated apoptosis, CD4 T cells were incu-
bated with 25 μg/ml of anti–Fas ligand mAb (NOK-1; Becton Dickinson) 
for 1 h, and then cocultured with VSMCs. TRAIL–DR5 receptor–ligand 
interactions were blocked with 25 μg/ml of mouse anti-human TRAIL 
mAb (RIK-2; Becton Dickinson) or 50 μg/ml anti-DR5 mAb (Diaclone). 
IgG mouse mAbs were used as isotype control.
RT-PCR and real-time PCR. Total RNA was purifi  ed from VSMCs using 
TRIzol (Life Technologies) and reverse-transcribed using AMV reverse tran-
scriptase (Roche Molecular Biochemicals). The liver tumor cell line HepG2 
served as positive control. cDNA was amplifi  ed with the following primers: DR4, 
5′-C  A  G  A  A  C  G  T  C  C  T  G  G  A  G  C  C  T  G  T  A  A  C  -3′ and 5′-A  T  G  T  C  C  A  T  T  G  C  C-
T  G  A  T  T  C  T  T  T  G  T  G  -3′; DR5, 5′-T  G  C  A  G  C  C  G  T  A  G  T  C  T  T  G  A  T  T  G  -3′ and 
5′-G  C  A  C  C  A  A  G  T  C  T  G  C  A  A  A  G  T  C  A  -3′; Fas, 5′-T  C  G  T  C  C  A  A  A  A  G  T  G  T  T-
A  A  T  G  C  C  -3′ and 5′-A  A  G  A  A  G  A  A  G  A  C  A  A  A  G  C  C  A  C  C  C  -3′; and β-actin, 
5′-C  A  T  G  G  T  G  G  T  G  C  C  G  C  C  A  G  A  C  A  G  -3′ and 5′-A  T  G  G  C  C  A  C  G  G  C  T  G  C-
T  T  C  C  A  G  C  -3′. RT-PCR products were separated by electrophoresis in 2.0% 
agarose containing ethidium bromide.
Tissue expression of TCR and TRAIL mRNA was analyzed by real-
time PCR. The following primers were used in these experiments: TCR 
α-chain, 5′-CCTTCAACA  A  C  A  G  C  A  T  T  A  T  T  C  C  A  G   -3′ and 5′-C  G  A  G  G-
G  A  G  C  A  C  A  G  G  C  T  G  T  C  T  T  A   -3′; and TRAIL, 5′-A  C  C  A  A  C  G  A  G  C  T  G  A-
A  G  C  A  G  A  T   -3′ and 5′-C  A  A  G  T  G  C  A  A  G  T  T  G  C  T  C  A  G  G  A   -3′. Transcripts 
for each gene were quantifi  ed using PCR instruments (Mx 3000 and Mx 4000; 
Stratagene). 1 μl cDNA was mixed with a total volume of 50 μl SYBR 
green master mix (5 μl 10 × PCR buff  er, 2.5 mM MgCl2, 0.2 mM each 
dNTPs, 0.025% BSA, 0.2 μl 5 U/μl Plt. Taq, 1:20,000 SYBR green, and 
0.1 μM each primer). PCR amplifi  cation protocol involved 40 cycles of de-
naturation at 95°C for 30 s, primer annealing at 55°C, and primer extension 
at 72°C for 60 s. cDNA concentrations were adjusted to 2 × 105 copies of 
β-actin. All PCR reactions were performed in triplicate.
Flow cytometry. For fl  ow cytometric analysis of surface death receptors, 
VSMC lines were stained with mouse anti–human DR4-PE, mouse anti–hu-
man DR5-PE (both eBioscience), and mouse anti–human Fas-PE mAb (BD 
Biosciences). Cells were analyzed on a FACSCalibur fl  ow cytometer (Becton 
Dickinson). Data were analyzed with WinMDI software (Joseph Trotter, 
Scripps Research Institute).
TRAIL expression on CD4 T cells was determined by two-color staining 
with anti-CD4-PerCP mAb and anti-TRAIL-PE mAb (both Becton Dickin-
son). PBMC were stimulated with 250 ng/ml anti-CD3 mAb (Ortho Biotech) or 
soluble IgG2a mAb for 2h in the presence of FcRII+ P815 cells. Again, liver tumor 
cells were used as positive controls.
Immunohistochemistry. Frozen tissues embedded in OCT compound 
were cut into 5-μm sections, fi  xed in cold acetone for 10 min, dried, and 
soaked in 1% paraformaldehyde solution for 5 min. After blocking endoge-
nous peroxidase and incubating with 5% normal goat serum (Invitrogen), the 
sections were stained for 1 h with affi   nity-purifi   ed rabbit anti–human 
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anti–rabbit Ig antibody (1:400; DAKO) for 30 min at room temperature. 
The color reaction was developed by ABC-peroxidase using 3, 3′-diamino-
benzidine (DAB). The tissue sections were washed with tap water, and the 
slides were counterstained with hematoxylin (Vector Laboratories, Inc.) for 
2 min. Serial sections were stained with anti α-SMC actin mAb (1:50) and 
anti-CD68 mAb; stains were developed with the DAKO ChemMate Envi-
sion kit (all DAKO Japan). Hematoxylin-eosin staining was performed on 
95% ethanol fi  xed sections; oil red O staining was performed on 10%   formalin 
fi  xed sections.
The TUNEL technique was used to quantify apoptotic cells in the tis-
sue. The plaque tissues were cut into 5-μm sections and analyzed by the In 
Situ Cell Death Detection Kit, AP (Roche). The percentage of TUNEL+ 
cells was calculated by counting TUNEL+ cells per total nuclei. Serial sec-
tions were stained with anti-CD3 (1:200; DAKO) and anti–α-SMC actin 
mAb (1A4, 1:200; DAKO) followed by secondary biotinylated goat anti–
mouse Ig antibody (1:400), ABC-peroxidase, and DAB.
CD4 T cells transfer into human artery SCID chimeras. 6–8-wk-old 
NOD.CB17-Prkdcscid/J mice (NOD-SCID) or NOD-129S7 (B6)-Rag1 
(tm1Mom) J mice (Jackson ImmunoResearch Laboratories) were engrafted 
with human carotid artery plaque tissue placed into a subcutaneous pocket 
on the midback. Engraftment of small tissue fragments (50–100 mm3) is 
rapid, and the graft is vascularized by day 7 with or without minimal murine 
infl  ammatory infi  ltrate within the implanted human tissue. A previous study 
has shown that the microvasculature within the graft is of human origin con-
necting to murine granulation tissue encapsulating the graft (62). All animal 
procedures were approved by the Animal Care and Use Committee. Non-
infl  amed sections of carotid artery walls lacking plaque formation were used 
as controls. On day 7 after implantation, the mice were injected intrave-
nously with 6 × 106 CD4 T cells or PBS. 24 h after the cell transfer, the ca-
rotid artery grafts were explanted and shock frozen in liquid nitrogen for 
mRNA analysis or embedded in OCT compound (Sakura Fine-Tek) for 
immunohistochemical analysis.
In selected adoptive transfer experiments, the carotid artery chimera 
mice were injected intravenously with control IgG2a mAb (300 μg/mouse), 
CD4 T cells (6 × 106 cells/mouse) combined with control IgG2a mAb (300 
μg/mouse), or CD4 T cells combined with anti-human TRAIL mAb (300 
μg/mouse; Becton Dickinson) on day 7 after tissue implantation. After 24 h, 
the carotid artery grafts were explanted, and tissue apoptosis rates were ana-
lyzed by TUNEL staining.
To quantify the damage of human VSMCs, blood was drawn from the 
mice before and 24 h after T cell transfer. LDH activity was measured using 
a Toxico Assay kit (Sigma-Aldrich). All LDH determinations were performed 
in triplicate, background absorbance rates were subtracted, and changes in 
LDH activity were expressed as the ratio of LDH levels before and after 
T cell transfers.
Statistical analysis. Data were analyzed by Student’s t test or Mann-Whit-
ney U test, when appropriate. Results are shown as mean ± SD, when para-
metric, and as box plots with medians and percentiles, when nonparametric 
testing was used.
Online supplemental material. Fig. S1 shows apoptosis rates assessed by 
nuclear fragmentation of DAPI-stained VSMCs and by Annexin V staining 
that were highly correlated (r = 0.95). CD4 T cells were cocultured with 
VSMCs, and induction of apoptosis was assessed by fl  uorescence micros-
copy. Intermediate stages of apoptosis were determined by staining with  Alexa 
Fluor-labeled Annexin V. Nuclear fragmentation was detected by DAPI 
staining. Membrane damage was measured by permeability to propidium io-
dide. The online supplemental material is available at http:// www. jem. org/ 
cgi/ content/ full/ jem. 20051062/ DC1. 
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